Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Clerkship | 4 | 2015 | 118 | 0.670 |
Why?
|
| Radiation Oncology | 4 | 2015 | 122 | 0.650 |
Why?
|
| Program Evaluation | 4 | 2018 | 311 | 0.530 |
Why?
|
| Clinical Competence | 4 | 2018 | 796 | 0.480 |
Why?
|
| Vitreoscilla | 2 | 2013 | 2 | 0.440 |
Why?
|
| Dietetics | 1 | 2013 | 3 | 0.430 |
Why?
|
| Nutritionists | 1 | 2013 | 4 | 0.430 |
Why?
|
| Truncated Hemoglobins | 1 | 2013 | 1 | 0.430 |
Why?
|
| Professional Role | 1 | 2013 | 41 | 0.420 |
Why?
|
| Tyrosine | 1 | 2013 | 133 | 0.410 |
Why?
|
| Carbon Monoxide | 1 | 2013 | 93 | 0.410 |
Why?
|
| Needs Assessment | 2 | 2014 | 159 | 0.390 |
Why?
|
| Research | 1 | 2013 | 252 | 0.390 |
Why?
|
| Oxygen | 1 | 2013 | 747 | 0.290 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 903 | 0.270 |
Why?
|
| Students, Medical | 4 | 2015 | 424 | 0.250 |
Why?
|
| Brachytherapy | 2 | 2021 | 121 | 0.250 |
Why?
|
| Plant Proteins | 3 | 2008 | 136 | 0.220 |
Why?
|
| Allergens | 3 | 2008 | 183 | 0.210 |
Why?
|
| Career Choice | 2 | 2014 | 148 | 0.200 |
Why?
|
| Methylmethacrylate | 1 | 2002 | 6 | 0.200 |
Why?
|
| Spinal Cord Compression | 1 | 2002 | 29 | 0.200 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 51 | 0.190 |
Why?
|
| Spinal Neoplasms | 1 | 2002 | 49 | 0.190 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 90 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 62 | 0.180 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 125 | 0.180 |
Why?
|
| Spinal Fusion | 1 | 2002 | 87 | 0.180 |
Why?
|
| Curriculum | 3 | 2015 | 574 | 0.180 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 152 | 0.180 |
Why?
|
| Crystallography, X-Ray | 6 | 2013 | 504 | 0.180 |
Why?
|
| Escherichia coli | 4 | 2013 | 611 | 0.150 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 298 | 0.150 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2007 | 7 | 0.150 |
Why?
|
| Crystallization | 8 | 2008 | 215 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 742 | 0.140 |
Why?
|
| Recombinant Proteins | 4 | 2013 | 1015 | 0.130 |
Why?
|
| Protein Structure, Secondary | 3 | 2013 | 335 | 0.130 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2015 | 49 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 377 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2018 | 381 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 406 | 0.110 |
Why?
|
| Pediatrics | 1 | 2018 | 361 | 0.110 |
Why?
|
| Queensland | 1 | 2013 | 5 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2013 | 39 | 0.110 |
Why?
|
| Achievement | 1 | 2013 | 29 | 0.110 |
Why?
|
| Phenylalanine | 1 | 2013 | 36 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 53 | 0.100 |
Why?
|
| Proline | 1 | 2013 | 56 | 0.100 |
Why?
|
| Alanine | 1 | 2013 | 85 | 0.100 |
Why?
|
| Models, Molecular | 3 | 2013 | 1324 | 0.100 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 284 | 0.100 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 399 | 0.100 |
Why?
|
| Globulins | 2 | 2008 | 2 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 181 | 0.100 |
Why?
|
| Ligands | 1 | 2013 | 453 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 413 | 0.100 |
Why?
|
| Seeds | 2 | 2008 | 59 | 0.090 |
Why?
|
| Antigens, Plant | 2 | 2007 | 14 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 304 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 148 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 982 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 561 | 0.090 |
Why?
|
| Binding Sites | 1 | 2013 | 1127 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 386 | 0.090 |
Why?
|
| Corylus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2011 | 267 | 0.080 |
Why?
|
| Humans | 16 | 2021 | 90568 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 1066 | 0.080 |
Why?
|
| Ginkgo biloba | 1 | 2008 | 7 | 0.080 |
Why?
|
| Pinus | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bertholletia | 1 | 2007 | 1 | 0.070 |
Why?
|
| Survival Rate | 3 | 2013 | 1899 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2007 | 30 | 0.070 |
Why?
|
| Arachis | 1 | 2007 | 11 | 0.070 |
Why?
|
| X-Ray Diffraction | 4 | 2008 | 130 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2007 | 233 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1096 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 1182 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 781 | 0.060 |
Why?
|
| Thioredoxins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 3692 | 0.060 |
Why?
|
| Spliceosomes | 1 | 2005 | 48 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1129 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2007 | 475 | 0.060 |
Why?
|
| Adult | 6 | 2021 | 26940 | 0.050 |
Why?
|
| Female | 6 | 2021 | 46855 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 3029 | 0.050 |
Why?
|
| Male | 6 | 2014 | 42931 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2018 | 0.050 |
Why?
|
| Protein Engineering | 1 | 2003 | 145 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 565 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 1357 | 0.050 |
Why?
|
| Cause of Death | 1 | 2002 | 270 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 2369 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 468 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 9323 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 222 | 0.040 |
Why?
|
| Aged | 4 | 2018 | 19404 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 1708 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
| Middle Aged | 4 | 2021 | 26327 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 270 | 0.040 |
Why?
|
| Seed Storage Proteins | 2 | 2007 | 2 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2007 | 102 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 3029 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 6812 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2005 | 1673 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1751 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2008 | 245 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 2893 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2015 | 73 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 108 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2015 | 278 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 37 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 646 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 135 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 128 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 320 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 188 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1240 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 633 | 0.030 |
Why?
|
| United States | 2 | 2018 | 7142 | 0.030 |
Why?
|
| Base Sequence | 2 | 2007 | 2329 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 324 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2702 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2342 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 589 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 168 | 0.020 |
Why?
|
| SEER Program | 1 | 2011 | 201 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 6425 | 0.020 |
Why?
|
| Insulin | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2667 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2607 | 0.020 |
Why?
|
| Soybean Proteins | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1440 | 0.020 |
Why?
|
| Salts | 1 | 2008 | 17 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 4059 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 94 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3273 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 2007 | 103 | 0.020 |
Why?
|
| Urination | 1 | 2007 | 39 | 0.020 |
Why?
|
| Food Hypersensitivity | 1 | 2008 | 72 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2008 | 160 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 185 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1193 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 145 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 354 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7216 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 138 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 3810 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2005 | 154 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 1170 | 0.010 |
Why?
|
| HIV Integrase | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cytochromes b | 1 | 2003 | 9 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2076 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2003 | 123 | 0.010 |
Why?
|
| Color | 1 | 2003 | 85 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 195 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 923 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 5365 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 446 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11932 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 728 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 8373 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 27691 | 0.010 |
Why?
|